Zubda Rashid, MD
Obstetrics & Gynecology · Newark, DENPI 1699707497
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 96 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $456 and has fallen 65.5% since, to $157 in 2025.
Across 96 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$249
- Amgen$189
- Daiichi Sankyo Inc.$189
- Bayer$114
- Mylan Pharmaceuticals Inc.$113
- Therapeuticsmd, Inc.$83
- plus $797 from 20 others
What the payments were for
- Food & beverage$1,68997%
- Education$463%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 17 | $249 |
| Amgen | 11 | $189 |
| Daiichi Sankyo Inc. | 10 | $189 |
| Bayer | 7 | $114 |
| Mylan Pharmaceuticals Inc. | 5 | $113 |
| Therapeuticsmd, Inc. | 4 | $83 |
| Astellas Pharma US Inc | 3 | $78 |
| Evofem Biosciences, Inc. | 5 | $76 |
| Coopersurgical, Inc. | 4 | $65 |
| Merck | 4 | $65 |
| Agile Therapeutics, Inc. | 3 | $65 |
| Covidien LP | 2 | $56 |
| Avion Pharmaceuticals | 3 | $53 |
| AMAG Pharmaceuticals, Inc. | 3 | $46 |
| Convatec Inc. | 1 | $41 |
| Abbott | 2 | $35 |
| Duchesnay USA Incorporated | 2 | $34 |
| Medtronic | 1 | $32 |
| Exeltis, USA Inc. | 2 | $26 |
| Organon | 1 | $24 |
| Myovant Sciences Inc. | 1 | $21 |
| Alydia Health | 1 | $19 |
| Lupin Inc. | 1 | $18 |
| Hologic Sales And Service, LLC | 1 | $16 |
| Shield Therapeutics Inc | 1 | $14 |
| Millicent US Inc | 1 | $14 |
How this compares
$1,735 in reported general payments places this provider in the 75th percentile of 139 obstetrics & gynecology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 11 | $255 |
| Metronidazole | 15 | $65 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Newark
- Anthony BellNewark$17K
- Richard DermanNewark$14K
- Gordon OstrumNewark$4K
- Colleen DeturkNewark$4K
- Patricia CiranniNewark$3K
- Michelle PacisNewark$3K
- Gregory DemeoNewark$3K
- Jose PicazoNewark$2K
- David FinkNewark$2K
- Stefanie MarshallNewark$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.